Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,616.00GBp
12:05pm EDT
Price Change (% chg)

-40.00p (-2.41%)
Prev Close
1,656.00p
Open
1,657.00p
Day's High
1,657.00p
Day's Low
1,611.00p
Volume
285,773
Avg. Vol
225,817
52-wk High
1,832.51p
52-wk Low
1,021.05p

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates in three business segments: Branded, Injectables, and Generics. The majority of its operations are... (more)

Overall

Beta: 0.84
Market Cap (Mil.): £3,287.58
Shares Outstanding (Mil.): 198.53
Dividend: 4.20
Yield (%): 0.72

Financials

  HIK.L Industry Sector
P/E (TTM): 17.41 32.64 33.50
EPS (TTM): 0.95 -- --
ROI: 23.44 18.10 17.33
ROE: 30.29 18.80 18.19
Search Stocks

UPDATE 2-Hikma Pharma cuts revenue forecast for branded drugs

* Revenue in injectibles business rises 41 pct to $346 mln

20 Aug 2014

Hikma first-half profit jumps on strong injectibles sales

Aug 20 - Hikma Pharmaceuticals Plc reported a 44 percent rise in first-half adjusted profit, helped by strong demand for its high-margin injectibles particularly in the United States.

20 Aug 2014

BRIEF-Hikma Pharma to buy Ben Venue's generic injectables factory

* Agreed with Ben Venue Laboratories, Inc. , part of Boehringer Ingelheim Group of companies, to acquire their generic injectables manufacturing site in Bedford, Ohio

24 Jul 2014

Emerging market fund managers ignore borders, chase profits

BOSTON - U.S. emerging market fund managers are paying less attention to where a company is located or listed than to whether it's making money, either as an advanced world company doing business in the developing world, or the other way around.

10 Jul 2014

BRIEF-Hikma buys assets of Bedford Laboratories for $300 mln

* Signed an asset purchase agreement with Ben Venue Laboratories Inc., a member of Boehringer Ingelheim Group of Companies

28 May 2014

BRIEF-Hikma raises operating margin forecast for injectables unit

* Has made a strong start to year and pleased to be reiterating guidance for 2014 of around 5 pct group revenue growth

15 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Peel Hunt
$12.00
Provider: Peel Hunt
$46.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks